Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins.
about
Heparan Sulfate Proteoglycan Metabolism and the Fate of Grafted TissuesModification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP.Versatile role of heparanase in inflammationHeparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis.Thrombotic processes in multiple sclerosis as manifestation of innate immune activation.Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease.A disaccharide that inhibits tumor necrosis factor alpha is formed from the extracellular matrix by the enzyme heparanase.'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis.Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.Role of endothelial heparanase in delayed-type hypersensitivity.Altering the course of proliferative nephritides: the challenge of the 1990s.The role of heparanase in pulmonary cell recruitment in response to an allergic but not non-allergic stimulus.Aspirin and multiple sclerosisHeparin and related drugs: beyond anticoagulant activity.Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus?The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention.Heparanase in inflammation and inflammation-associated cancer.Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation.The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells.A rapid quantitative assay for the detection of mammalian heparanase activity.Heparin as a therapy for atherosclerosis: preliminary observations on the intrapulmonary administration of low-dose heparin in the morning versus evening gauged by its effect on blood variables.The efficacy of recombinant human activated protein C (rhAPC) vs antithrombin III (at III) vs heparin, in the healing process of partial-thickness burns: a comparative study.Heparanase: From basic research to therapeutic applications in cancer and inflammation.Low-molecular-weight heparins do not modify obliterative airway disease in rat tracheal allografts.Heparin and low-molecular-weight heparin (enoxaparin) significantly ameliorate experimental colitis in rats.Cell surface expression of the 300 kDa mannose-6-phosphate receptor by activated T lymphocytes.Heparin, a potent releasing agent of extracellular superoxide dismutase (EC-SOD C), suppresses ischaemic paw oedema in mice.The effect of low molecular weight heparin (fragmin) on myocardial neutrophil accumulation and infarct size in a rat model of myocardial infarction.Heparan sulfate proteoglycans modulate monocyte migration across cerebral endothelium.Microbial metabolites and derivatives targeted at inflammation and bone diseases therapy: chemistry, biological activity and pharmacology.Detection of Glycan Shedding in the Blood: New Class of Multiple Sclerosis Biomarkers?Heparan sulfate is a plasma biomarker of acute cellular allograft rejection
P2860
Q26797410-97A46CCF-0019-4FDF-91FD-A50062B38E9FQ33714011-28C17DDD-5235-4008-BEAE-62A0C3B3FC36Q33770777-2480BFC4-7C39-4F90-BB4A-3FCD93A86B1CQ33833954-7D3B1B00-A491-47F4-9B02-66582901792BQ33851359-D4E11654-A043-47B4-80B0-8110C553290CQ34078523-1BBE73B2-3915-4AD7-B452-94BB3B56FC5BQ34285445-298CB098-5086-4B44-AE48-A45005C3837BQ34409059-8B9B083A-96C6-4AB4-84EC-A14F763265CBQ34476372-B9E3A0C7-095C-41CD-91C8-46B4D5965968Q34557376-B8A10755-2539-4C13-A88C-07C8027C90B9Q35154105-5D974DE4-85D5-4F8B-9BAB-046A36324D0CQ35651533-E036CB61-BB22-43C2-AD52-1CDADACBD3A7Q35678040-004AACBE-1471-48FB-8B2E-35E35A46F73BQ37105310-08D9AC43-D447-4E80-B4D4-A9197EFB5068Q37120570-2B777584-A10E-436B-ACC4-CEA8D899BC1FQ37808230-E1B5D478-B295-432D-8914-1BFAE934B84BQ38080632-E909048F-A74D-4065-BC41-EAA7CF8E6AFCQ38985052-8821563F-07E2-4A56-9FF7-DDBF299ABF71Q40529900-EEE82FAF-DEBA-4FA4-92B1-CE5F261A5C68Q40774057-65DDCC38-AC54-43CB-8BC1-19ADACCE9977Q41102250-8F5C9A1A-28C3-4170-B3C7-D00D83F969C9Q41821849-A652513A-C13E-4301-A96A-8372AB0384FDQ41887896-D293181E-010F-4801-9FC9-B108DB7AF6FCQ42587945-9FE90D14-63F6-46D8-8F81-3991C90C9C66Q42879801-D92247CF-CA3F-405B-B5C3-DC254A48DEE7Q43742733-31190701-6A61-47C9-B686-797C3F4BC7BCQ43742831-8098A167-AC72-49FB-B2E1-706B623E8FD3Q44641125-CF069FAD-D3B8-4C6D-9BB1-85B5FE2B0B8DQ47332717-F4E46603-0794-46D3-AA25-4D7FFE4DF142Q47711360-8293CC14-CC9A-42CD-816C-5CEDD687642CQ52845977-74F9C621-1605-4FC6-9C8D-AC471D0BAFEBQ55262746-AFD253AF-2BF0-4337-863D-855A08E0480AQ58797992-6DE90B01-8241-432F-8652-9877202A6259
P2860
Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins.
description
1989 nî lūn-bûn
@nan
1989 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մարտին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Suppression of experimental au ...... ls with low doses of heparins.
@ast
Suppression of experimental au ...... ls with low doses of heparins.
@en
Suppression of experimental au ...... ls with low doses of heparins.
@nl
type
label
Suppression of experimental au ...... ls with low doses of heparins.
@ast
Suppression of experimental au ...... ls with low doses of heparins.
@en
Suppression of experimental au ...... ls with low doses of heparins.
@nl
prefLabel
Suppression of experimental au ...... ls with low doses of heparins.
@ast
Suppression of experimental au ...... ls with low doses of heparins.
@en
Suppression of experimental au ...... ls with low doses of heparins.
@nl
P2093
P2860
P356
P1476
Suppression of experimental au ...... ls with low doses of heparins.
@en
P2093
I Vlodavsky
Y A Mekori
Y Naparstek
P2860
P304
P356
10.1172/JCI113953
P407
P577
1989-03-01T00:00:00Z